Latest News - ONL Therapeutics

Wednesday, May 17, 2017

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

ONL Therapeutics announced that it has closed a $4.25 million Series A round of fundraising, which, combined with the recently announced $1 million grant from the National Eye Institute, will primaril…

Read the full story

Tuesday, March 21, 2017

ONL Therapeutics Receives Nearly $1 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program

ONL Therapeutics announced that the company has been awarded a Commercialization Readiness Pilot (CRP) grant of approximately $1 million from the National Eye Institute (NEI) to continue advancement o…

Read the full story

Thursday, February 11, 2016

ONL Therapeutics Receives Orphan Drug Designation from FDA for ONL1204 for Treatment of Retinal Detachment

ONL Therapeutics announced that the FDA has granted orphan drug designation to ONL1204 for the treatment of retinal detachment, according to a company news release. ONL1204 is a novel, first-in-class …

Read the full story

Wednesday, October 14, 2015

ONL Therapeutics Announces Formation of Scientific Advisory Board

ONL Therapeutics announced the formation of a scientific advisory board comprised of five of the world’s premier retinal disease thought leaders. The newly appointed scientific advisory board wi…

Read the full story

Monday, June 15, 2015

ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases

ONL Therapeutics provided an update on the company’s ongoing drug development program to block the programmed cell death (apoptosis) of photoreceptors.  Death of photoreceptors, which occur…

Read the full story